Nicholas L. Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicholas L. Yan has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jeffery W. Kelly
Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA
8 shared publications - Gareth John Morgan
Boston University School of Medicine
5 shared publications - Arthur Alves Melo
Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
3 shared publications - Daniel R. Southworth
Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA
3 shared publications - Eric Tse
Institute for Neurodegenerative Diseases, University of California, San Francisco, USA
3 shared publications - Gregory E. Merz
Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
3 shared publications
Latest Publications
- Open Access
Cryo-EM Structures of Infectious Low-Twist α-Synuclein Filaments in Lewy Bodies
α-Synuclein (aSyn) aggregation within Lewy bodies underlies Parkinson’s disease and associated dementias. These aggregates are often comprised of amyloid filaments, most of which appear untwisted or have extremely low twist, complicating high-resolution structural determination by cryogenic electron microscopy (cryo-EM). Here, we isolated filaments from the brain tissue of a patient with dementia with Lewy bodies and show infectivity in a cell line system that propagates Lewy aSyn. Then, we determined 2.3–2.9 Å cryo-EM structures of low-twist aSyn filaments from this tissue and from a publicly available Parkinson’s disease dementia dataset. In both structures, the protofilament adopts a fold highly similar to the canonical Lewy fold with conserved cofactor and peptidic densities. Compared to previously resolved high-twist filaments, the low-twist filament is left-handed and flattened along the filament axis, resulting in register shifts of interlayer contacts, while preserving the overall architecture. Our results establish that low-twist filaments, which include over 75% of disease-associated Lewy aSyn amyloids, share a common structural core with high-twist forms and are the predominant aSyn species in samples that engage in templated infection.
Open AccessCryo-EM Structures of Infectious Low-Twist α-Synuclein Filaments in Lewy Bodies
α-Synuclein (aSyn) aggregation within Lewy bodies underlies Parkinson’s disease and associated dementias. These aggregates are often comprised of amyloid filaments, most of which appear untwisted or have extremely low twist, complicating high-resolution structural determination by cryogenic electron microscopy (cryo-EM). Here, we isolated filaments from the brain tissue of a patient with dementia with Lewy bodies and show infectivity in a cell line system that propagates Lewy aSyn. Then, we determined 2.3–2.9 Å cryo-EM structures of low-twist aSyn filaments from this tissue and from a publicly available Parkinson’s disease dementia dataset. In both structures, the protofilament adopts a fold highly similar to the canonical Lewy fold with conserved cofactor and peptidic densities. Compared to previously resolved high-twist filaments, the low-twist filament is left-handed and flattened along the filament axis, resulting in register shifts of interlayer contacts, while preserving the overall architecture. Our results establish that low-twist filaments, which include over 75% of disease-associated Lewy aSyn amyloids, share a common structural core with high-twist forms and are the predominant aSyn species in samples that engage in templated infection.
- 29 June 2026
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (19) , 169917
Small molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry
- 29 June 2026
- Published by Elsevier in Journal of Molecular Biology
- Vol. 438 (19) , 169917
Small molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry
- Open Access
Resolving the Activation Mechanism of the Human 20S Proteasome
Proteasome activators (PAs) bind the α-subunits of the human 20S proteasome (h20S), opening the “gates” and allowing entry of substrate proteins. Aging is associated with diminished proteasome activity, leading to interest in understanding this activation mechanism. Evolving models have been proposed regarding PAs C-terminal tails, yet the critical molecular contacts for gate-opening are unclear. Here, we show a conserved leucine in the 5th position (P5) of the C-terminus is essential for h20S gate opening. By engineering C-termini in a model activator, PA26 E102A , we show mutations to P5 systematically modulate proteasome activity in vitro and in cells. Structures of PA26 E102A :h20S complexes at 2.7-3.2 Å resolution identify interactions between P5 and a conserved arginine in the h20S, leading to partial or full gate opening. These results clarify the essential contacts required for h20S gate opening, potentially enabling design of proteasome activation therapies.
Open AccessResolving the Activation Mechanism of the Human 20S Proteasome
Proteasome activators (PAs) bind the α-subunits of the human 20S proteasome (h20S), opening the “gates” and allowing entry of substrate proteins. Aging is associated with diminished proteasome activity, leading to interest in understanding this activation mechanism. Evolving models have been proposed regarding PAs C-terminal tails, yet the critical molecular contacts for gate-opening are unclear. Here, we show a conserved leucine in the 5th position (P5) of the C-terminus is essential for h20S gate opening. By engineering C-termini in a model activator, PA26 E102A , we show mutations to P5 systematically modulate proteasome activity in vitro and in cells. Structures of PA26 E102A :h20S complexes at 2.7-3.2 Å resolution identify interactions between P5 and a conserved arginine in the h20S, leading to partial or full gate opening. These results clarify the essential contacts required for h20S gate opening, potentially enabling design of proteasome activation therapies.
- Open Access
Small molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry
Immunoglobulin light chains, a component of antibodies, can misfold and aggregate to cause systemic AL amyloidosis. Aggregation, including amyloid fibril formation, requires unfolding of the full-length light chain from its native state, and in most cases aberrant proteolysis. Small molecules that bind to the native state of light chains to stabilize them against conformational excursions and proteolysis are under development as drug candidates for AL amyloidosis. Since each patient has a unique light chain sequence, a challenge for candidate stabilizer drugs is to bind multiple light chains and suppress their dynamics. Here, we used hydrogen-deuterium exchange measured by mass spectrometry to characterize the binding of six small molecule stabilizers to eleven different λ light chain proteins. Despite structural and dynamic differences among the light chains, the binding of the most efficacious stabilizer molecule led to increased protection from hydrogen exchange, consistent with reduced local and global unfolding. Protection upon binding was most prominent in residues within complementarity determining region 3 and framework region 4 of the light chain variable domains, which undergo major conformational changes enabling amyloid formation. Stabilizer binding also reduced the rate at which all light chains were cleaved by protease. These data show that these stabilizers suppress the range of conformational dynamics associated with light chain aggregation, supporting their therapeutic potential.
Open AccessSmall molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry
Immunoglobulin light chains, a component of antibodies, can misfold and aggregate to cause systemic AL amyloidosis. Aggregation, including amyloid fibril formation, requires unfolding of the full-length light chain from its native state, and in most cases aberrant proteolysis. Small molecules that bind to the native state of light chains to stabilize them against conformational excursions and proteolysis are under development as drug candidates for AL amyloidosis. Since each patient has a unique light chain sequence, a challenge for candidate stabilizer drugs is to bind multiple light chains and suppress their dynamics. Here, we used hydrogen-deuterium exchange measured by mass spectrometry to characterize the binding of six small molecule stabilizers to eleven different λ light chain proteins. Despite structural and dynamic differences among the light chains, the binding of the most efficacious stabilizer molecule led to increased protection from hydrogen exchange, consistent with reduced local and global unfolding. Protection upon binding was most prominent in residues within complementarity determining region 3 and framework region 4 of the light chain variable domains, which undergo major conformational changes enabling amyloid formation. Stabilizer binding also reduced the rate at which all light chains were cleaved by protease. These data show that these stabilizers suppress the range of conformational dynamics associated with light chain aggregation, supporting their therapeutic potential.
- Open Access
- 7 November 2024
- Published by Wiley in FEBS Letters
- Vol. 599 (1) , 33-40
Cryo‐EM structure of a novel α‐synuclein filament subtype from multiple system atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by accumulation of α‐synuclein cross‐β amyloid filaments in the brain. Previous structural studies of these filaments by cryo‐electron microscopy (cryo‐EM) revealed three discrete folds distinct from α‐synuclein filaments associated with other neurodegenerative diseases. Here, we use cryo‐EM to identify a novel, low‐populated MSA filament subtype (designated Type I2) in addition to a predominant class comprising MSA Type II2 filaments. The 3.3‐Å resolution structure of the Type I2 filament reveals a fold consisting of two asymmetric protofilaments, one of which adopts a novel structure that is chimeric between two previously reported protofilaments. These results further define MSA‐specific folds of α‐synuclein filaments and have implications for designing MSA diagnostics and therapeutics.
- 7 November 2024
- Published by Wiley in FEBS Letters
- Vol. 599 (1) , 33-40
Open AccessCryo‐EM structure of a novel α‐synuclein filament subtype from multiple system atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by accumulation of α‐synuclein cross‐β amyloid filaments in the brain. Previous structural studies of these filaments by cryo‐electron microscopy (cryo‐EM) revealed three discrete folds distinct from α‐synuclein filaments associated with other neurodegenerative diseases. Here, we use cryo‐EM to identify a novel, low‐populated MSA filament subtype (designated Type I2) in addition to a predominant class comprising MSA Type II2 filaments. The 3.3‐Å resolution structure of the Type I2 filament reveals a fold consisting of two asymmetric protofilaments, one of which adopts a novel structure that is chimeric between two previously reported protofilaments. These results further define MSA‐specific folds of α‐synuclein filaments and have implications for designing MSA diagnostics and therapeutics.
- Open Access
Structure of a novel α-synuclein filament fold from multiple system atrophy
Multiple system atrophy (MSA) is a synucleinopathy, a group of related diseases characterized by the accumulation of α-synuclein aggregates in the brain. In MSA, these aggregates form glial cytoplasmic inclusions, which contain abundant cross-β amyloid filaments. Structures of α-synuclein filaments isolated from MSA patient tissue were determined by cryo–electron microscopy (cryo-EM), revealing three discrete folds that are distinct from α-synuclein filaments associated with other synucleinopathies. Here, we use cryo-EM classification methods to characterize filaments from one individual with MSA and identify a novel, low-populated MSA filament fold (designated Type I 2 ) in addition to a predominant class comprising MSA Type II 2 . The 3.3-Å resolution structure of the Type I 2 filament reveals a fold consisting of two asymmetric protofilaments. One is identical to a previously solved Type I protofilament, while the second adopts a novel fold that is chimeric between two previously reported Type I and II protofilaments. These results further define disease-specific folds of α-synuclein filaments that develop in MSA and have implications for the design of therapeutic and diagnostic molecules that target disease.
Open AccessStructure of a novel α-synuclein filament fold from multiple system atrophy
Multiple system atrophy (MSA) is a synucleinopathy, a group of related diseases characterized by the accumulation of α-synuclein aggregates in the brain. In MSA, these aggregates form glial cytoplasmic inclusions, which contain abundant cross-β amyloid filaments. Structures of α-synuclein filaments isolated from MSA patient tissue were determined by cryo–electron microscopy (cryo-EM), revealing three discrete folds that are distinct from α-synuclein filaments associated with other synucleinopathies. Here, we use cryo-EM classification methods to characterize filaments from one individual with MSA and identify a novel, low-populated MSA filament fold (designated Type I 2 ) in addition to a predominant class comprising MSA Type II 2 . The 3.3-Å resolution structure of the Type I 2 filament reveals a fold consisting of two asymmetric protofilaments. One is identical to a previously solved Type I protofilament, while the second adopts a novel fold that is chimeric between two previously reported Type I and II protofilaments. These results further define disease-specific folds of α-synuclein filaments that develop in MSA and have implications for the design of therapeutic and diagnostic molecules that target disease.
- Open Access
The conformational landscape of human transthyretin revealed by cryo-EM
Transthyretin (TTR) is a natively tetrameric thyroxine transporter found in blood and cerebrospinal fluid whose misfolding and aggregation causes transthyretin amyloidosis. A rational drug design campaign identified the small molecule tafamidis (Vyndaqel/Vyndamax) as an effective stabilizer of the native TTR fold, and this aggregation inhibitor is regulatory agency-approved for the treatment of TTR amyloidosis. Despite 50 years of structural studies on TTR and this triumph of structure-based drug design, there remains a notable dearth of structural information available to understand ligand binding allostery and amyloidogenic TTR unfolding intermediates. We used single-particle cryo-electron microscopy (cryo-EM) to investigate the conformational landscape of this 55 kiloDalton tetramer in the absence and presence of one or two ligands, revealing inherent asymmetries in the tetrameric architecture and previously unobserved conformational states. These findings provide critical mechanistic insights into negatively cooperative ligand binding and the structural pathways responsible for TTR amyloidogenesis. This study underscores the capacity of cryo-EM to provide new insights into protein structures that have been historically considered too small to visualize and to identify pharmacological targets suppressed by the confines of the crystal lattice, opening uncharted territory in structure-based drug design.
Open AccessThe conformational landscape of human transthyretin revealed by cryo-EM
Transthyretin (TTR) is a natively tetrameric thyroxine transporter found in blood and cerebrospinal fluid whose misfolding and aggregation causes transthyretin amyloidosis. A rational drug design campaign identified the small molecule tafamidis (Vyndaqel/Vyndamax) as an effective stabilizer of the native TTR fold, and this aggregation inhibitor is regulatory agency-approved for the treatment of TTR amyloidosis. Despite 50 years of structural studies on TTR and this triumph of structure-based drug design, there remains a notable dearth of structural information available to understand ligand binding allostery and amyloidogenic TTR unfolding intermediates. We used single-particle cryo-electron microscopy (cryo-EM) to investigate the conformational landscape of this 55 kiloDalton tetramer in the absence and presence of one or two ligands, revealing inherent asymmetries in the tetrameric architecture and previously unobserved conformational states. These findings provide critical mechanistic insights into negatively cooperative ligand binding and the structural pathways responsible for TTR amyloidogenesis. This study underscores the capacity of cryo-EM to provide new insights into protein structures that have been historically considered too small to visualize and to identify pharmacological targets suppressed by the confines of the crystal lattice, opening uncharted territory in structure-based drug design.
- 6 June 2023
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 75, 102319
Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis
- 6 June 2023
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 75, 102319
Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis
- Open Access
- 12 April 2023
- Published by Wiley in Israel Journal of Chemistry
- Vol. 63 (10-11)
Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand‐Binding Cavity
Stabilization of amyloidogenic immunoglobulin light chains (LCs) by binding of small molecule “kinetic stabilizers” is under development as a novel treatment for light chain amyloidosis. From a high‐throughput screen, we previously identified 16 full‐length (FL) LC stabilizers from five distinct chemotypes. We then obtained structural biological information on two classes of hits, coumarins and hydantoins, revealing that both chemotypes bind to a pocket at the VL−VL interface of the FL LC dimer. Here, we report crystal structures of three screening hits from two other chemotypes, diaryl hydrazones and sulfones, in complex with an amyloidogenic FL LC. While two of these hits bind to the previously identified pocket, one diaryl hydrazone binds to a different pocket bisected by the C2 symmetry axis of the dimer. These data further expand on the FL LC stabilizer‐binding surface that could be used in design of more potent FL LC aggregation inhibitors.
- 12 April 2023
- Published by Wiley in Israel Journal of Chemistry
- Vol. 63 (10-11)
Open AccessCrystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand‐Binding Cavity
Stabilization of amyloidogenic immunoglobulin light chains (LCs) by binding of small molecule “kinetic stabilizers” is under development as a novel treatment for light chain amyloidosis. From a high‐throughput screen, we previously identified 16 full‐length (FL) LC stabilizers from five distinct chemotypes. We then obtained structural biological information on two classes of hits, coumarins and hydantoins, revealing that both chemotypes bind to a pocket at the VL−VL interface of the FL LC dimer. Here, we report crystal structures of three screening hits from two other chemotypes, diaryl hydrazones and sulfones, in complex with an amyloidogenic FL LC. While two of these hits bind to the previously identified pocket, one diaryl hydrazone binds to a different pocket bisected by the C2 symmetry axis of the dimer. These data further expand on the FL LC stabilizer‐binding surface that could be used in design of more potent FL LC aggregation inhibitors.
- 19 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 60, 128571
Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site
- 19 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 60, 128571
Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site